Literature DB >> 15917509

Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes.

Jim Zhen Wu1, Gary Larson, Heli Walker, Jae Hoon Shim, Zhi Hong.   

Abstract

Many nucleoside analog drugs, such as ribavirin and viramidine, are activated or metabolized in vivo through 5'-phosphorylation. In this report, we determined the steady-state kinetic parameters for 5'-monophosphorylation of ribavirin and viramidine by adenosine kinase. The apparent Km for ribavirin is 540 microM, and k(cat) is 1.8 min-1. Its catalytic efficiency of 3.3 x 10(-3) min-1 . microM-1 is 1,200-fold lower than that of adenosine. In contrast to the common belief that ribavirin is exclusively phosphorylated by adenosine kinase, cytosolic 5'-nucleotidase II was found to catalyze ribavirin phosphorylation in vitro. The reaction is optimally stimulated by the physiological concentration of ATP or 2,3-bisphosphoglycerate. In phosphate-buffered saline plus ATP and 2,3-bisphosphoglycerate, the apparent Km for ribavirin is 88 microM, and k(cat) is 4.0 min-1. These findings suggest that cytosolic 5'-nucleotidase II may be involved in ribavirin phosphorylation in vivo. Like ribavirin, viramidine was found to be phosphorylated by either adenosine kinase or cytosolic 5'-nucleotidase II, albeit with a much lower activity. The catalytic efficiency for viramidine phosphorylation is 10- to 330-fold lower than that of ribavirin, suggesting that other nucleoside kinase(s) may be involved in viramidine phosphorylation in vivo. Both ribavirin and viramidine are not phosphorylated by deoxycytidine kinase and uridine-cytidine kinase. The coincidence of presence of high concentrated 2,3-bisphosphoglycerate in erythrocytes suggests that cytosolic 5'-nucleotidase II could play an important role in phosphorylating ribavirin and contribute to anabolism of ribavirin triphosphate in erythrocytes. Elucidation of ribavirin and viramidine phosphorylation mechanism should shed light on their in vivo metabolism, especially the ribavirin-induced hemolytic anemia in erythrocytes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917509      PMCID: PMC1140532          DOI: 10.1128/AAC.49.6.2164-2171.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

Review 1.  Side effects of therapy of hepatitis C and their management.

Authors:  Michael W Fried
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

2.  Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia.

Authors:  Masato Homma; Yasushi Matsuzaki; Yoichi Inoue; Minoru Shibata; Keiji Mitamura; Naomi Tanaka; Yukinao Kohda
Journal:  Clin Gastroenterol Hepatol       Date:  2004-04       Impact factor: 11.382

3.  The metabolism of ribavirin in erythrocytes and nucleated cells.

Authors:  T Page; J D Connor
Journal:  Int J Biochem       Date:  1990

4.  Structure-activity studies on mammalian adenosine kinase.

Authors:  M C Maj; B Singh; R S Gupta
Journal:  Biochem Biophys Res Commun       Date:  2000-08-28       Impact factor: 3.575

5.  Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions.

Authors:  Jim Zhen Wu; Heli Walker; Johnson Y N Lau; Zhi Hong
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

6.  Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-beta-D-Ribofuranosyl-3-nitropyrrole.

Authors:  Daniel A Harki; Jason D Graci; Victoria S Korneeva; Saikat Kumar B Ghosh; Zhi Hong; Craig E Cameron; Blake R Peterson
Journal:  Biochemistry       Date:  2002-07-23       Impact factor: 3.162

7.  Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals.

Authors:  Chin-chung Lin; Li-Tain Yeh; Domenico Vitarella; Zhi Hong
Journal:  Antivir Chem Chemother       Date:  2003-05

Review 8.  Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design.

Authors:  Jim Zhen Wu; Chin-chung Lin; Zhi Hong
Journal:  J Antimicrob Chemother       Date:  2003-09-01       Impact factor: 5.790

9.  Mammalian 5'-nucleotidases.

Authors:  Vera Bianchi; Jozef Spychala
Journal:  J Biol Chem       Date:  2003-08-28       Impact factor: 5.157

10.  Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections.

Authors:  Robert O Baker; Mike Bray; John W Huggins
Journal:  Antiviral Res       Date:  2003-01       Impact factor: 10.103

View more
  13 in total

1.  Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.

Authors:  Liviawati S Wu; Joseph E Rower; James R Burton; Peter L Anderson; Kyle P Hammond; Fafa Baouchi-Mokrane; Gregory T Everson; Thomas J Urban; David Z D'Argenio; Jennifer J Kiser
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.

Authors:  Utthara Nayar; Jouliana Sadek; Jonathan Reichel; Denise Hernandez-Hopkins; Gunkut Akar; Peter J Barelli; Michelle A Sahai; Hufeng Zhou; Jennifer Totonchy; David Jayabalan; Ruben Niesvizky; Ilaria Guasparri; Duane Hassane; Yifang Liu; Shizuko Sei; Robert H Shoemaker; J David Warren; Olivier Elemento; Kenneth M Kaye; Ethel Cesarman
Journal:  J Clin Invest       Date:  2017-05-15       Impact factor: 14.808

Review 3.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Authors:  Katherine L B Borden; Biljana Culjkovic-Kraljacic
Journal:  Leuk Lymphoma       Date:  2010-10

4.  Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin.

Authors:  Nirav R Shah; Amanda Sunderland; Valery Z Grdzelishvili
Journal:  PLoS One       Date:  2010-06-22       Impact factor: 3.240

5.  Analysis of ribavirin mutagenicity in human hepatitis C virus infection.

Authors:  Stéphane Chevaliez; Rozenn Brillet; Ester Lázaro; Christophe Hézode; Jean-Michel Pawlotsky
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

6.  The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes.

Authors:  Christopher J Endres; Aaron M Moss; Ban Ke; Rajgopal Govindarajan; Doo-Sup Choi; Robert O Messing; Jashvant D Unadkat
Journal:  J Pharmacol Exp Ther       Date:  2009-01-22       Impact factor: 4.030

7.  4-Pyridone-3-carboxamide-1-β-D-ribonucleoside triphosphate (4PyTP), a novel NAD metabolite accumulating in erythrocytes of uremic children: a biomarker for a toxic NAD analogue in other tissues?

Authors:  Elena Synesiou; Lynnette D Fairbanks; H Anne Simmonds; Ewa M Slominska; Ryszard T Smolenski; Elizabeth A Carrey
Journal:  Toxins (Basel)       Date:  2011-06-07       Impact factor: 4.546

Review 8.  Effect of ITPA Polymorphism on Adverse Drug Reactions of 6-Mercaptopurine in Pediatric Patients with Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.

Authors:  Yeonhong Lee; Eun Jeong Jang; Ha-Young Yoon; Jeong Yee; Hye-Sun Gwak
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-29

Review 9.  The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design.

Authors:  Annelies Stevaert; Lieve Naesens
Journal:  Med Res Rev       Date:  2016-08-29       Impact factor: 12.944

Review 10.  Nucleosides for the treatment of respiratory RNA virus infections.

Authors:  Paul C Jordan; Sarah K Stevens; Jerome Deval
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.